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Reduced and oxidized glutathione concentrations in post-mortem brain tissue from the substantia nigra of control subjects and patients with 
neuropathologically confirmed Parkinson's disease were measured by a coulometric method using high-pressure liquid chromatography and electro- 
chemical detection. Reduced glutathione concentrations were decreased in the substantia nigra of parkinsonian patients compared with controls. 
Differences in the concentration of oxidized glutathione and in the percentage of oxidized glutathione of the total gtutathione were not observed 
between parkinsonian and control subjects. The finding that oxidized glutathione is not decreased in Parkinson's disease suggests that the decrease 
in reduced glutathione is not exclusively the consequence of neuronal loss in the substantia nigra but may indicate a state of oxidative stress. 
Parkinson's disease is a slowly progressive neurode- 
generative disorder which is characterized pathologically 
by the loss of pigmented neurones from the substantia 
nigra. The aetiology of this degeneration is unknown. 
However, endogenous radicals generated by hydrogen 
peroxide [3], toxic ~,fl-unsaturated aldehydes which 
could react with reduced glutathione (GSH) [13, 19, 23] 
or metabolic ompounds of the catecholamine metabo- 
lism such as 5-S-cysteinyldopamine [14] and 6-hy- 
droxydopamine [7] could all potentially trigger Parkin- 
son's disease. Toxic compounds formed in the brain are 
normally inactivated by various protective mechanisms. 
These mechanisms, however, may be impaired in Parkin- 
son's disease, e.g. reduced activity ofcatalase, peroxidase 
and glutathione peroxidase and diminished concentra- 
tions of GSH have been found in the substantia nigra in 
Parkinson's disease [1, 7, 10, 12]. GSH in the substantia 
nigra and enzymes that utilize GSH for free radical de- 
toxification, such as glutathione peroxidase and glutathi- 
one-S-transferase, probably play an important role in 
protecting dopaminergic nigrostriatal neurones from 
damage by 1-methyl-4-phenyl-l,2,3,6-tetrahydropyrid- 
ine (MPTP), or from other MPTP-like neurotoxins 
which may cause Parkinson's disease in humans. Re- 
duced levels of GSH have been found in the brainstem of 
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mice following administration of MPTP [13, 23]. The 
MPTP-induced depletion of GSH in the brainstem of 
mice was prevented by pre-treatment with antioxidants 
[23]. 
In Parkinson's disease the surviving neurones of the 
nigrostriatal pathway exhibit an increased dopamine 
turnover [6]. This could theoretically be associated with 
oxidative stress as a consequence of increased produc- 
tion of hydrogen peroxide during the oxidative deamina- 
tion of dopamine by monoamine oxidase (MAO). In the 
mouse, a reserpine-induced increase in pre-synaptic 
dopamine turnover caused a rise in the level of oxidized 
glutathione (glutathione disulfide, GSSG). The forma- 
tion of GSSG could be blocked by the MAO-A inhibitor 
clorgyline [18]. Oxidative metabolism of dopamine in the 
brain is associated with the production of hydrogen per- 
oxide and may be reflected by oxidation of GSH to 
GSSG [15, 21]. We have therefore xamined the concen- 
trations of GSH and GSSG in the substantia nigra of 
patients with Parkinson's disease and matched control 
subjects. 
Brain tissue from the substantia nigra was obtained at 
autopsy from four patients with Parkinson's disease and 
from four age-matched control subjects with no evidence 
of neurological or psychiatric disease (Table I). The clini- 
cal diagnosis was confirmed in all cases by neuropathol- 
ogical examination. Patients with Parkinson's disease 
had all received L-DOPA combined with the peripheral 
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decarboxylase inhibitor benserazide, amantadine sulfate 
and anticholinergics. The brain tissue was frozen at 
-80°C until analysis. 
GSH and GSSG were measured by a coulometric 
method using high-pressure liquid chromatography 
(HPLC) and electrochemical detection (ESA coulochem 
detector). The effluent was 0.015 M o-phosphoric acid. 
Compounds were separated on an RP-18 Spherisorb 5/,, 
I I00 x 4.6 ram) column. Flow rate was 0.5 ml/min. For 
electrochemical oxidation the detectors were held at 
+-0.02 V (TI) and +0.30 V (T2). As reference substance, 
10yl of 3.25/aM GSH (Sigma, St. Louis, MO, USA)in 
0.015 M o-phosphoric acid were used. GSSG was re- 
duced at pH 7.5 by fl-nicotinamide-dinucleotide phos- 
phate and glutathione reductase (EC 1.6.4.2.) to regener- 
ate GSH. Brain tissue was homogenized in 0.015 M o- 
phosphoric acid and centrifuged at 15,000 g for 10 rain at 
4°C. The supernatants were used for HPLC injections 
[17]. All results were analyzed using Wilcoxon's rank- 
sum test [22]. 
The concentration of GSH was reduced in the substan- 
tia nigra of patients with Parkinson's disease compared 
with control subjects (Table I). Differences in the GSSG 
concentration and in the percentage of GSSG of the total 
glutathione between parkinsonian and control subjects 
were not observed. 
The present study has investigated GSH and GSSG 
concentrations in the substantia nigra in normal controls 
and in Parkinson's disease. The GSH and GSSG concen- 
trations measured in control subjects are well in accord 
with the results of previous tudies [16]. Levels of GSSG 
were about 2.3% of the total glutathione. These results 
conflict with those indicating that about 90% of the glu- 
tathione in the substantia nigra is in the oxidized form 
[10]. This study found that most of the total glutathione 
in various areas of the human brain is in the form of 
GSSG [10], whereas other authors described GSSG as 
1.2% or less of total glutathione in autopsy specimens of 
human brain and in fresh samples of monkey brain [16]. 
GSSG levels comprising 41 100% of the total glutathi- 
one [10, I I] are difficult to explain, since they would 
point to a very unusual state of the redox couple GSH/ 
GSSG in the human brain. The factors responsible for 
the conflicting results need to be elucidated but may in- 
clude differences in tissue storage, tissue extraction or 
analytical methods. 
The decreased concentration of GSH in the substantia 
nigra in Parkinson's disease could be the result of neu- 
ronal loss. In fact, a positive correlation has been shown 
between the GSH content and the severity of neuronal 
depletion in the parkinsonian brain [12]. However, neu- 
ronal degeneration does not appear to be the only expla- 
nation for the GSH reduction observed, since GSSG was 
not decreased to the same extent as GSH and the per- 
centage from the total glutathione of GSSG was slightly 
but not significantly increased (Table l). An elevated 
level of GSSG could therefore serve as an indicator of 
oxidative stress [15, 21]. GSH is synthesized from its con- 
stituent amino acids by the sequential action of ATP- 
dependent enzymes, gamma-glutamylcysteine synthetase 
and GSH synthetase. Amino acid precursors for the syn- 
thesis of GSH are glycine, cysteine and glutamate. In 
addition to the reaction processes of GSH as mentioned 
above, loss of GSH in the substantia nigra in Parkinson's 
disease may be the result of a disturbance in the biosyn- 
thesis. A decrease in available GSH would reduce the 
capacity of the neurones to detoxify hydrogen peroxide 
and increase the risk of free radical |\)rmation and lipid 
peroxidation. Increased membrane lipid peroxidation 
has indeed been shown in the substantia nigra in Parkin- 
son's disease [5], suggesting that free radicals are gener- 
ated and contribute to neuronal damage. 
Elevated striatal GSSG levels t\)llowing reserpine ad- 
ministration indicate that increased opamine turnover 
is associated with oxidative stress [18]. Raised dopamine 
turnover in Parkinson's disease [6] increases the risk of 
peroxidative damage in the vicinity of dopamine-con- 
taining neurones. This damage could be exacerbated by 
c-DOPA therapy although there is no direct evidence of 
mediation by the drug. The capability of i.-deprenyl to 
delay the progression of early Parkinson's disease [9.20] 
and to increase life-expectancy when combined with t,- 
DOPA [2] may be explained by the present results, t_- 
Deprenyl reduced oxidative stress associated with in- 
creased turnover of dopamine and limited the accumula- 
TABLE 1 
PATIENT CHARACTERISTICS AN[) LEVELS OF REDUCED 
AND OXIDIZED GLUTATHIONE IN POST-MORTEM SUB- 
STANTIA NIGRA 
Neurochemical values are the means (,ug,'g fresh weight) + S.E.M. 
GSH. rednced glutathione; GSSG, oxidized glutathione; GSSG %, per- 
centage of oxidized glutathione of the total glutathione. 
Control subjects Park01son's disease 
I. 4) (t~ 4) 
Mean age 72 76 
Age range 66 83 62 91 
Sex 2 F. 2 M I F. 3 M 
Post-mortcm time (h) 4.3 + (I,4 4.3 :+ 1.3 
Cell loss and presence o[ No Yes 
Lewy bodies in midbrain 
GSH (./-/~'gt 92.8 + 12.6 49.3 + 4.6 
GSSG (ug/g) 2.3 ~ 0.6 1.7 + 0.5 
GSSG % 2.3 + 0.3 3.3 ~_ 1.0 
" P < 0.05, Wilcoxon's rank-sum lest. 
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tion of GSSG in the striatum of rodents [4]. Therapy with 
L-deprenyl may therefore reduce oxidative stress as a 
consequence of increased dopamine turnover in the sur- 
viving nigrostriatal neurones in Parkinson's disease. 
The present results do not allow any definite conclu- 
sions on the role of GSH and GSSG in the protection 
from free radicals in the substantia nigra in Parkinson's 
disease. Further studies using larger sample sizes are nec- 
essary to confirm these observations. 
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